Treatment of multiple myeloma
Brouet, J.C.
La Revue du Praticien 43(3): 321-325
1993
ISSN/ISBN: 0035-2640 PMID: 8502963 Document Number: 416273
The various chemotherapeutic regimens in multiple myeloma allow only a mean survival of less than three years. Polychemotherapy has at best a minor advantage over monochemotherapy. High dose chemotherapy followed by hematopoietic stem cell grafts yields a notable percentage of apparent complete remission. The best therapeutic choices as well as the introduction of new drugs such as alpha interferon still needs prospective evaluation.